Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Trodelvy® is the first treatment for metastatic triple-negative breast cancer shown to improve progression-free survival and overall survival SHANGHAI, April 9, 2021 /PRNewswire/ -- Everest Medi...

Full "IntellAsia: Resources" article